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INTRODUCTION  
Sublingual tablets are the one that dissolves when held 
beneath the tongue, permitting direct absorption of the 
active ingredient by the oral mucosa. Sublingual tablets 
are to be placed under the tongue and produce immediate 
systemic effect by enabling the drug absorbed directly 
through mucosal lining of the mouth beneath the tongue.  
Several type of migraine is given below: 
• Migraine without aura(common Migraine) 
• Migraine with aura(classic Migraine) 
• Complicated Migraine 
A migraine headache can cause intense throbbing or 
pulsing in one area of the head is commonly 
accompanied by nausea, vomiting, and extreme 
sensitivity to light and sound. Migraine attacks can cause 
significant pain for hours to days. Migraine affects 
around one in ten people. They are three times more 
common in females and tend to affect young people who 
are otherwise healthy. Naratriptan is a 5-HT1 agonist use 
for the treatment of migraine headaches. It is available in 
strengths of 1 and 2.5 mg as conventional and orally 
disintegrating tablets. It is a second generation triptan. 
Naratriptan completely absorbed following oral 
administration. The mean oral absolute bioavailability of 
the tablet is about 60%. This clearly indicates that 
Naratriptan have first pass metabolism problem. The 
metabolic pathway of Naratriptan included primarily 
hepatic. In vitro, Naratriptan is metabolized by a wide 
range of cytochrome P450 isoenzymes into a number of 
methods may not always be convenient for the patient. 
Therefore, there is growing interest in developing new, 
non-parenteral, reliable and convenient dosage forms 
using administration routes where a rapidly dissolved 
drug is immediately absorbed into the systemic 
circulation. The advantage of the sublingual drug 
delivery is that the drug can be directly absorbed into 
systemic circulation bypassing enzyme degradation in 
the gut and liver. In addition, the thin sublingual mucosa 
(about 190 um compared to 500-800 um of the buccal 
mucosa) and the abundance of blood supply at the 
sublingual region allow excellent drug penetration 
(absorption) to achieve high plasma drug concentration 
with a rapid onset of action 1-12 
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ABSTRACT 
Naratriptan is used for the treatment of migraine. Formulation and Evaluation of sublingual tablets of Naratriptan for pre and 
post Compression parameters was undertaken.  The tablets were prepared by direct compression method using super 
disintegrates. After selection of superdisintegrants tablets were prepared by using polymer for reducing the flushing action of 
saliva and provide enough time for drug absorbed. The prepared tablets were evaluated for their physical and chemical 
property. The permeation study was performed on Goat mucosa for optimized batch. No interactions were found between drug 
and excipients. Formulation F2 containing Crosspovidone shows immediate drug release. Formulation F6 containing Chitoson 
shows fast drug release as compared to superdisintegrants alone. Sublingual tablets were prepared by direct compression 
method using Crosspovidone as a superdisintegrants. But it is more effective in combination with Chitoson. As a result, 
sublingual tablet administration of Naratriptan formulated with appropriate excipients and especially with Chitoson seems 
promising alternative to traditional routes. 
Keyword:-Sublingual delivery, Naratriptan, Superdisintegrants, Chitoson, Permeability, Migraine, Crosspovidone 
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MATERIAL AND METHODS 
Material 
Naratriptan was received as gift sample from Sun 
Pharmaceutical Ltd, Baroda. All other excipients were 
used of analytical grades.                                                                                                                                  
Methods
 
Direct compression is a process by which tablets are 
compressed directly from mixtures of the drug and 
excipients, without any preliminary treatment. All the 
excipients and drug were weighed in electrolab weighing 
machine and mixed for 5 min and compressed directly by 
using B tooling machine and using 6 mm concave punch 
13, 14
. 
 
Formulation Table 
Table 1: Formulation containing super disintegrate with polymer 
Ingredients F1(mg) F2(mg) F3(mg) F4(mg) F5(mg) F6(mg) 
Naratriptan 2.5 2.5 2.5 2.5 2.5 2.5 
β-cyclodextrin 10 10 10 10 10 10 
Crosspovidone 3 6 9 6 6 6 
Chitoson - - - 0.5 2 5 
Camphor 30 30 30 30 30 30 
Mannitol 10 10 10 10 10 10 
MCC 40 37 34 36.5 35 32 
Talc 2 2 2 2 2 2 
Mg stearate 2.5 2.5 2.5 2.5 2.5 2.5 
Total 100 100 100 100 100 100 
 
Evaluation Parameters 
15 
Uniformity of Weight (Weight Variation Test)  
Twenty tablets were weighed individually. Average 
weight was calculated from the total weight of all tablets. 
The individual weights were compared with the average 
weight. The percentage difference in the weight variation 
should be within the permissible limits. The percent 
deviation was calculated using the following formula 16.                
                                                                                                    
Percentage Deviation=  
Individual weight - Average weight / Average weight x 100 
 Hardness Test 
The hardness of tablets was tested using Monsanto 
hardness tester. The average of the three determinations 
was determined and reported. The force is measured in 
Kg/cm
2, 17. 
Friability Test  
Roche friabilator was used to measure the friability of 
the tablets. Ten tablets were weighed collectively and 
placed in the chamber of the friabilator. In the friabilator, 
the tablets were exposed to rolling, resulting from free 
fall of tablets within the chamber of the friabilator. It was 
rotated for 100 rotations at a rate of 25 rpm. After 100 
rotations the tablets were redusted and weighed 
collectively and % loss was calculated 18.           
Disintegration time 
The disintegration time for sublingual tablets was 
determined by using USP disintegration test apparatus. 
The limit for disintegration was not more than 2 minutes 
at 37 
0
C. Six tablets were placed individually in each 
tube of disintegration test apparatus and discs were 
placed. The water bath was maintained at 37 0C ± 0.5 0C 
and the times taken for all tablets to disintegrate 
completely were noted 19, 20.  
Wetting Time 
Wetting time of dosage form is related with the contact 
angle. Wetting time of the mouth dissolving tablets is 
another important parameter, which needs to be assessed 
to give an insight into the disintegration properties of the 
tablets; a lower wetting time implies a quicker 
disintegration of the tablet. A circular tissue paper of 10 
cm diameter was placed in a Petridish with 10 ml of 
water containing Eosin water soluble dye. A tablet was 
carefully placed on the surface of the tissue paper. The 
time required for water to reach upper surface of the 
tablet was noted as wetting time 21 
In Vitro Drug Release 
In vitro  drug release of the samples was carried out 
using USP-type II dissolution apparatus (paddle type). 
The dissolution medium, 900 ml of pH 6.8 phosphate 
buffer maintaining the temperature of 37±0.5 oC and rpm 
of 50.The apparatus was allowed to run for 20 min 
.Samples were withdrawn at 5 mins interval up to 20 
mins. The fresh dissolution medium was replaced every 
time with the same quantity of the sample. Collected 
samples were suitably diluted with dissolution medium 
and analyzed by UV spectrophotometer (Shimadzu 
1700) at λmax 226 nm.  The cumulative percentage drug 
release was calculated 22. 
Ex- vivo Permeation Study 
Ex vivo permeation study was carried out for optimized 
batch (F6) with modified horizontal diffusion chambers 
in phosphate buffer (pH 6.8), maintained at 37±0.5 0C. 
Goat sublingual membrane obtains from slloter house 
was used as a permeation barrier. Samples were collected 
at predetermined time intervals and analyzed by using 
UV spectrophotometer at λmax 226nm 
23, 24 
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Table 2: Complex of Drug with β-Cyclodextrin 
Batch Naratriptan: β-CD Solubility Taste masking* 
A 1:2 1.8 1 
B 1:4 2.1 2 
C 1:6 1.9 0 
D 1:8 1.6 1 
E 1:10 1.4 1 
*: 0-Good, 1-Very good, 2-Excellent 
Table 3: Post-compression studies 
Formulation 
Hardness (Kg/cm
2
) 
(±S.D)(n=3) 
Disintegration Time 
(Sec) (±S.D)(n=6) 
Friability (%) 
 
   Wetting Time 
(Sec) (±S.D)(n=3) 
F1 2.4±0.56 95 ±1.10 0.38 83.00±0.68 
F2 3.8±0.67 90±0.56 0.23 78.0±0.50 
F3 2.8±0.52 105±0.85 0.63 89.34±0.78 
F4 2.7±0.10 45±1.78 0.57 38.33±0.96 
F5 2.5±0.19 50±0.65 0.62 34.46±0.86 
F6 3.6±0.36 35±1.46 0.32 28.55±1.02 
 
 
Figure 1: In-Vitro drug release study of F1-F3 
Batches. 
  
Figure 2: In-Vitro drug release study of F4- F6 
Batches
 
 
Figure 3: Comparison of dissolution time and Permeation time 
0
20
40
60
80
100
120
0 5 10 15 20 25
Dissolution
Permeation
%
C
D
R
TIME(min)
Brahmbhatt et al                                      Journal of Drug Delivery & Therapeutics; 2014, 4(4), 19-23 22 
Table 4: Stability Study 
Formulation code Parameter Storage time 
 
 
F6 
 
 
Drug content 
Initial 1months 2months 3months 
99.87% 98.23% 96.89% 96.50% 
 
 
Figure 4: Comparison of dissolution of optimized batch (F6) of initial and after 3 months 
 
RESULTS AND DISSCUSION 
Naratriptan tablets were prepared by using 
Crosspovidone and Chitoson as a disintegrants at 
different concentration as shown in table no 1 
respectively. Total numbers of six formulations were 
prepared by direct compression technique. The data 
obtained of post compression parameters such as 
hardness, friability, weight variation, disintegration time 
and wetting time  was done as shown in table no 3 
respectively. The hardness was found to be in the range 
of 2.4 to 3.8 Kg/cm2 for all the formulations indicating 
good mechanical strength with an ability to withstand 
physical and mechanical stress conditions while 
handling. In all the formulations the friability values are 
less than 1% and meet the IP limits. All the tablets 
passed weight variation test as the percentage weight 
variation was within the pharmacopoeia limits. The 
weight of all tablets was found to be uniform with low 
standard deviation values indicating efficient mixing of 
drug, disintegrants and excipients. The results of in vitro 
wetting time and in vitro disintegration time of all the 
tables were found to be within the prescribe limits and 
satisfy the criteria of fast dissolving tables. Among all 
the formulations F6 formulation results were better than 
the other formulations. In F6 formulation has the 
minimum DT was found to be 28s. So it was found that 
at F6 formulation have superdisintegrants showed less 
D.T and good hardness. And it also gives the better 
immediate release action  
CONCLUSION 
In present study sublingual tablets of Naratriptan tablet 
were prepared by direct compression to achieve the 
antimigrant effect. Different batches were prepared by 
using Crosspovidone as a superdisintegrants by direct 
compression method. The optimized batch of 
Crosspovidone was further mixed with polymer i.e. 
Chitoson. There after batches were evaluated for 
different evaluation parameters. From that combination 
Crosspovidone and Chitoson showed better results. So it 
is more effective in combination with Chitoson. As a 
result, sublingual tablet administration of Naratriptan 
formulated with appropriate excipients and especially 
with Chitoson seems promising alternative to traditional 
routes. The tablets containing Chitoson polymer showed 
the high degree of Disintegration Time. Formulations F6 
containing Chitoson show better immediate release 
action.
 
REFERENCES 
1. Hooda R, Tripathi M, A Review on Oral Mucosal Drug 
Delivery System, The pharma innovation, 2011; 13-19.  
2. Narang N, Sharma J, Sublingual mucosa as a route for 
systemic drug delivery, International Journal of Pharmacy and 
Pharmaceutical Sciences, 2011; 18-21.  
3. Saraganachari A, M.pharm thesis, Formulation and 
development of sublingual tablet of an anti asthmatic drug, 
Rajiv Gandhi University, 2006.  
Brahmbhatt et al                                      Journal of Drug Delivery & Therapeutics; 2014, 4(4), 19-23 23 
4. Pryse-Phillips WE, Dodick DW, Guidelines for the non-
pharmacological management of migraine in clinical practice, 
Canadian Headache Society, CMAJ, 1988; 147-154. 
5. Spierings E L, Symptomatology and pathogenesis of 
migraine, Journal of Pediatric Gastroenterology & Nutrition, 
1995; 37-41.  
6. Lobo BL, Symptomatic Pharmacotherapy of Migraine, 
Journal of clinical therapeutics, 1999; 7: 1118-1130.  
7. Lanteri-Minet M and Desnuelle C, Migraine and 
mitochondrial dysfunction, Review Neurologique, 1996; 23-
48.   
8. Mauskop A and Altura BM, Role of magnesium in the 
pathogenesis and treatment of Migraines, Journal of Clinical 
Neuroscience, 1998; 7-24.  
9.  Machelska H and Cabot PJ, Pain control in inflammation 
governed by selecting, Journal of Nature Medicine, 1998; 17-
25.  
10.  Doenicke  A and Moss  J  Toledano.Administration of  H1 
and H2 antagonists for chemoprophylaxis:  a  double-blind, 
placebo-controlled study  in  healthy  volunteers, Journal of 
Clinical Pharmacology,1997; 6-14.  
11. Goadsby PJ, The pharmacology of headache, Progress in 
Neurobiology, 2000; 62: 509-525.   
12. Peatfield RC, Relationships between foods, wine, and beer-
precipitated migrainous headaches, Headache, 1995; 7-75.  
13. Bayrak Z, Tas C, Tasdemir U,Formulation of zolmitriptan 
sublingual tablets prepared by direct compression with 
different polymers: In vitro and in vivo evaluation, European 
Journal of Pharmaceutics and Biopharmacutics, 2011; 78: 
499–505. 
14.  Shangraw RF, Direct Compression Tableting, Encyclopaedia 
of Pharmaceutical Technology (4), 1988; 85-160. 
15. Birhade ST, Banker B .Preparation and Evaluation of 
Cyclodextrin Based Binary Systems for Taste Masking. 
International Journal of Pharmaceutical Sciences and Drug 
Research, 2010; 2(3): 199-203.  
16. Kumar R, Patil S, Patil MB,Formulation Evaluation of Mouth 
Dissolving Tablets of Fenofibrate Using Sublimation 
Technique, International Journal of Chem, Tech Research, 
2009; 1(4): 840-850. 
17. Grover I, Agarwal G, Formulation and Evaluation of 
Sublingual Tablets of Lisinopril, Journal of Scientific & 
Industrial Research, 2012; 71: 413-417. 
18. Bhanj SB, Ellaiah HK, Formulation and Evaluation of 
Perindopril Sublingual Tablets, International Journal of 
Research in Pharmaceutical and Biomedical Sciences, 2011; 
2(3):1193-1198. 
19. Chaudhari P, Formulation and evaluation of Rizatriptan 
Benzoate Fast Disintegrating Tablet,   Research Journal of 
Pharmaceutical, Biological and Chemical Sciences, 2011; 
482-488. 
20. Bharbwaj V,Formulation and evaluation of fast disintegrating 
sublingual tablets of amlodipine besylate using different 
superdisintegrants, International Journal of Pharmacy and 
Pharmaceutical Sciences,2010; 2(3). 
21. Rachid O, Rawas-Qalaji M, Simon R,Rapidly-disintegrating 
Sublingual tablets of Epinephrine: Role of Ingredients in 
formulation development, European Journal of Pharmaceutics 
and Biopharmacutics ,2012. 
22. Sheeba FR, Giles DA, Formulation and Evaluation of 
Nifidipine Sublingual Tablet, Asian Journal of 
Pharmaceutical and Clinical Research, 2009; 2(3): 44-48. 
23.  Kumari A, Sahoo S.Uv-spectroscopic methods for estimation 
of rizatriptan benzoate in pharmaceutical preparations.  
International Journal of chemtech Research. 2010; 2(1): 653-
659.  
24. Indian Pharmacopoeia, Govt. of India “Ministry of health & 
family welfare” The controller & publication, Delhi.2007; 
Vol-II: 477-478.   
 
 
   
 
 
 
